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Shortly after the pioneering Montag-
nier/Gallo discoveries of HIV as the etio-
logic agent of AIDS, the CD4 antigen was
identified as the primary receptor for HIV
entry. The focus of the present story begins
with 1986 report from Richard Axel’s group
that recombinant human CD4 conferred
permissiveness to HIV-1 infection when
expressed on diverse human cell types, but
not on mouse cells. The block was at an
early replication step after virion binding,
perhaps virus internalization (1).
My entry into the HIV/AIDS field came
at a particularly opportune time (1987) and
place (Laboratory of Viral Diseases, NIAID,
NIH, headed by Bernie Moss). I was inter-
ested in learning the vaccinia virus-based
system for recombinant protein expression,
and applying it to study HIV entry. Bernie’s
group had generated a vaccinia recombi-
nant encoding HIV-1 Env that induced
robust CD4-dependent cell fusion as mea-
sured by syncytia (2). The strictly cytoplas-
mic nature of the vaccinia replication cycle
turned out to provide a fortuitous advan-
tage for studying Env, since it obviated the
as-yet unrecognized need for co-expression
of HIV rev to export unspliced Env RNA
out of the nucleus; moreover, the extremely
broad host range of vaccinia enabled stud-
ies of Env-mediated fusion with a variety
of cell types from diverse species. In a
reductionist system using the correspond-
ing vaccinia recombinants, we showed that
cells expressing HIV-1 Env formed syncy-
tia when mixed with cells (lymphoid and
non-lymphoid) expressing human CD4,
provided the latter were of human origin
(3). Parallel results were obtained by other
groups (4, 5).
Was this phenomenon due to a require-
ment for an additional human-specific fac-
tor, or to a dominant restrictive feature of
the non-human cells? In collaboration with
Robert Blumenthal’s group at NCI, NIH,
we demonstrated that CD4-expressing
transient hybrids between human and
murine cells were fusion-permissive, argu-
ing against the non-human restriction
model (6). These findings in the reduction-
ist cell fusion system were consistent with
studies by others examining HIV infec-
tion of transient or stable or cell hybrids
(4, 5). Thus, by the early 1990s, it was
evident that the CD4-human cell require-
ment was manifest at the level of Env-CD4-
mediated fusion/entry, apparently reflect-
ing target cell expression of an essential
human-specific cofactor (perhaps a 2nd
receptor, or “coreceptor”).
Further adding to my good fortune was
my partnering with postdoc Tom Fuerst
in the Moss lab, who had led their devel-
opment of the vaccinia/T7 hybrid expres-
sion system. They had shown that a tar-
get gene linked to the phage T7 promoter
is activated by the vaccinia-encoded T7
RNA polymerase expressed in the same
cell; the presence of all components in
the cytoplasm leads to robust transient
expression of the target gene (7). I real-
ized that this system could be adapted to
study Env-receptor-mediated cell fusion by
expressing the vaccinia-encoded T7 poly-
merase in one cell partner and introducing
a reporter gene (e.g., the E. coli LacZ gene)
linked to the T7 promoter in the other;
reporter expression would be triggered in
the cytoplasm of fused cells. Postdocs Ofer
Nussbaum and Chris Broder in my group
demonstrated the highly sensitive and spe-
cific nature of this reporter assay and its
superiority over the subjective and labori-
ous semi-quantitative syncytium-counting
assay (8). Specific fusion was observed
when Env-expressing “effector cells” were
mixed with CD4-expressing“target cells”; a
robust β-galactosidase signal was detected
at 2–3 h, either by in situ staining or col-
orimetric assay of detergent cell lysates
(Figure 1A). Importantly, the reporter
assay corroborated the requirement that
CD4 be expressed on a human cell, whereas
Env could be on a human or non-human
cell. Membrane vesicle transfer experi-
ments demonstrated that the fusion defi-
ciency of CD4-expressing non-human cells
was not due to their detrimental modifica-
tion of CD4.
The specificity of Env-mediated
fusion/entry took on an additional layer
of complexity beginning in the late 1980s
with the growing awareness that different
HIV-1 isolates displayed markedly distinct
in vitro tropisms for infection of different
CD4-positive target cell types (10). Some
isolates infected CD4+ continuous T cell
lines (and non-lymphoid human cell lines
such as HeLa-CD4 transformants) but not
primary macrophages; others displayed
the reverse tropism, infecting primary
macrophages but not CD4+ T cell lines.
The terms “T cell line-tropic” (TCL-tropic)
and “macrophage-tropic” (M-tropic) were
used to distinguish these variants. Both
phenotypes replicated in primary CD4+
T cells. This phenotypic distinction was
more than simply a laboratory curiosity;
in the real world of human HIV infec-
tion, the isolates obtained shortly after
transmission and throughout the asymp-
tomatic phase invariably displayed the
M-tropic phenotype; TCL-tropic vari-
ants emerged only (years) later, during
the transition to the symptomatic phase
and progression to AIDS (and not in all
cases). Studies from many groups in the
early-mid 1990s pinpointed Env as the
principle viral determinant mediating this
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FIGURE 1 | (A) Reporter gene assay for HIV-1 Env/CD4-mediated cell fusion. Effector HeLa cells
expressed vaccinia-encoded HIV Env wild type (WT) or a non-functional uncleaved mutant (unc) and
were transfected with a plasmid containing the LacZ gene linked to the T7 promoter. Target HeLa cells
expressed vaccinia-encoded T7 RNA polymerase with (+) or without (−) CD4. Duplicate cell mixtures
were incubated at 37°C for 2.5 h and β-galactosidase was measured in one set by in situ staining
(photomicrographs) and in the other by colorimetric assay of detergent cell lysates (insets, arbitrary
units). Adapted from Ref. (8). (B) Demonstration of fusin’s function as an entry receptor for TCL-tropic
HIV-1.Top panel. Cell fusion assay. Effector NIH 3T3 cells expressed vaccinia-encoded Env from the
indicated TCL-tropic or M-tropic HIV-1 isolate as well as T7 RNA polymerase. Target NIH 3T3 cells were
co-transfected with the plasmid containing the LacZ gene linked to the T7 promoter plus either a
control plasmid (filled bars) or a plasmid encoding fusin (cross-hatched bars). Cell mixtures were
incubated at 37°C for 3 hr, and β-galactosidase was measured by the colorimetric assay of detergent
cell lysates. Bottom panel. HIV-1 infection assay. PBMCs were pre-incubated with the indicated
concentrations of purified rabbit antibodies [preimmune, and immune against the fusin N-terminus],
then infected with HIV-1 LAV (left, TCL-tropic) or Ba-L (right, M-tropic). Culture supernatants were
assayed by ELISA for p24 content at day 7. Results for each isolate are expressed as the percentage of
p24 produced at each antibody concentration compared to the control value with no antibody. From Ref.
(9). (C). Rare detection of the name “fusin.” From the Maryland Department of Motor Vehicles.
tropism phenotype (4, 5). Using the reduc-
tionist cell fusion assay, Chris Broder in
my group demonstrated a marked corre-
lation between the fusion specificities of
vaccinia-encoded HIV-1 Env glycoproteins
and the infection tropisms of the strains
from which they were derived (11). Sub-
sequently, postdocs Ghalib Alkhatib and
Chris performed fusion assays with tran-
sient hybrids between continuous cell lines
and macrophages; the results suggested
that the fusion specificities were attribut-
able to distinct cellular cofactors (core-
ceptors?) mediating TCL- vs. M-tropism
rather than to cell type-specific fusion
restriction factors (12). Identification of
these cofactors thus became the focal point
of extensive searches by many groups
worldwide; numerous candidate molecules
were proposed (specific proteins, glycol-
ipids), but these did not withstand detailed
experimental scrutiny (4, 5).
Our initial identification efforts focused
on the TCL-tropic cofactor, for the
simple reason that it appeared to be
expressed in diverse human cell lines
(e.g., HeLa), thereby providing a tech-
nical advantage compared to primary
macrophages. Yu Feng, a new post-
doc in the group, initiated a strategy
based on mRNA microinjection. At the
outset, we committed to an unbiased
approach with no preconceived notions
about what type of protein we were seeking;
our only criterion was gain-of-function
in a fusion assay with CD4-expressing
non-human host cells; microinjection of
mRNA from a permissive human cell
type (e.g., HeLa) should confer fusion-
permissiveness. But what host cells to
use? We knew that an NIAID investiga-
tor in a nearby lab, Phil Murphy, was
doing microinjection experiments in Xeno-
pus oocytes. Hearing that Phil was a
highly congenial colleague, we approached
him with the idea even though his
research interests centered on a subject
that had nothing to do with HIV, i.e.,
receptors for chemokines (small proteins
that function as chemoattractants guid-
ing leukocyte migration). Phil expressed
enthusiasm, but we soon realized that
the experimental features of the Xeno-
pus oocyte system were incompatible with
Env/CD4-mediated cell fusion. A more
expeditious approach employing mam-
malian cells was required.
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We then turned to the idea of
transfecting a cDNA library from a
fusion-permissive human cell type into
a CD4-expressing non-human cell and
testing for fusion gain-of-function. We
knew that CD4-expressing HeLa cells were
highly permissive fusion targets (presum-
ably because of high cofactor expression)
whereas CD4-expressing murine NIH 3T3
cells were consistently refractory (presum-
ably cofactor-negative); moreover, a HeLa
cDNA library was commercially avail-
able. We devised a functional screen-
ing assay involving transfection of the
HeLa cDNA library into 3T3 target cells
expressing vaccinia-encoded human CD4
(and T7 RNA polymerase); a small frac-
tion of these cells would become fusion-
permissive due to expression from the rare
cDNA encoding the cofactor, and would
fuse with added effector cells express-
ing a vaccinia-encoded TCL-tropic Env
(and containing a transfected plasmid
with the T7 promoter/Lac Z reporter).
Staining in situ for β-galactosidase would
reveal cell fusion. In the very first experi-
ments (May 1995), the library-transfected
target cells yielded decisively more β-
galactosidase-positive cells compared to
controls. After several rounds of library
sub-fractionation and screening, a single
cDNA clone was isolated that conferred
robust fusion-permissiveness to the CD4-
expressing murine cells.
DNA sequencing results obtained at
the end of July 1995 indicated that the
~1.7 kb cDNA insert encoded a 352 amino
acid protein with 7 putative transmem-
brane domains, i.e., a likely member of
the G protein-coupled receptor superfam-
ily. The nucleotide sequence had been
reported by several groups during the
previous 2–3 years, but the normal func-
tion of the protein was unknown. Since
the only observed activity was in ren-
dering CD4-expressing non-human cells
permissive for HIV-1 fusion, we gave it
the name “fusin.” During the following
months, we accumulated critical experi-
mental evidence proving fusin’s role as
the sought-after entry cofactor for TCL-
tropic HIV, including (a) gain-of-function
experiments showing that fusin rendered
CD4-expressing non-human cells permis-
sive for HIV-1 Env-mediated cell fusion
and virus infection, (b) specificity assays
demonstrating fusion gain for TCL-tropic
but not M-tropic Envs (Figure 1B, top),
(c) loss-of-function experiments demon-
strating the fusion-blocking and infection-
neutralizing activity of rabbit antibodies
against the putative N-terminal domain
of fusin, and specificity based on selec-
tive antibody blocking for TCL-tropic but
not M-tropic HIV-1 (Figure 1B, bottom),
and (d) Northern blots demonstrating
the presence of fusin mRNA in permis-
sive human target cells and its absence
from unusual non-permissive human tar-
gets (and, of course, from non-human
cells). Taken together, these results con-
vincingly established fusin as the critical
entry cofactor for TCL-tropic HIV-1.
Some intriguing implications became
apparent during the course of our work.
First, the previous cDNA cloning papers
indicated that the closest amino acid
sequence homology with a protein of
known function was with the human recep-
tor(s) for interleukin 8, a CXC chemokine.
How ironic, since one of the two back-
to-back 1991 papers describing that first
cloning of a human chemokine recep-
tor was from none other than our nigh-
collaborator Phil Murphy! Second, the pos-
sibility that fusin might be a chemokine
receptor took on greatly added significance
with a December 1995 paper from Paolo
Lusso and Fiorenza Cocchi in Bob Gallo’s
lab at the NCI, NIH; these investigators
demonstrated that three CC chemokines,
RANTES, MIP-1α, and MIP1-β accounted
for the HIV-1 soluble suppressive activity
released by CD8 T cells (13), a phenom-
enon first described by Jay Levy’s group
during the preceding decade. Most inter-
estingly, these CC chemokines suppressed
a M-tropic much more than a TCL-tropic
strain. Thus, the fusin discovery, together
with the Lusso suppressive chemokines,
provided a possible clue to the identity
of the M-tropic cofactor: perhaps it was
a chemokine receptor, in this case for
RANTES, MIP-1α and MIP1-β.
I presented our fusin findings at a Key-
stone meeting in Santa Fe NM in February
1996, well before we were ready to submit
the manuscript. Perhaps naively, I disclosed
not only the evidence supporting fusin as
the TCL entry cofactor but also the full
amino acid sequence of the protein. The
brush fire was now ignited, in both the HIV
and chemokine research communities. But
just in time for my group came the next
irony. In late January 1996, we attended a
seminar by Phil in which he revealed his
lab’s cloning of a new chemokine receptor
called CCR5, with precisely the specificity
for the Lusso chemokines. Surely, there
must be some connection with HIV, but
what could that be? There we sat, with
our knowledge of fusin, and our fledg-
ling struggles to find the M-tropic cofac-
tor by a similar functional cloning strat-
egy using a cDNA library from primary
macrophages. After some urgent pleas from
the postdocs, I relinquished my stubborn
adherence to the intellectual purity of the
unbiased library screening approach and
agreed instead to go for the direct kill. I
contacted Phil in early March 1996, at last
beginning a most productive collaboration.
While attending another Keystone meet-
ing at Hilton Head SC later that month,
I phoned the lab and got the great news
from Ghalib – he had the first data indicat-
ing a role for CCR5 as the M-tropic entry
cofactor. The definitive experiments were
completed over the next couple of months.
By the time, our fusin paper came out
in May 1996 (9), the firestorms were rag-
ing in full. I give here only brief sum-
maries, since there are fascinating stories
to be told by other investigators who made
major contributions to these developments
[see reviews in Ref. (4, 5, 14, 15)]. On
the HIV front, five independent papers
(including ours) describing CCR5 as the
essential entry cofactor for M-tropic HIV-1
were published within a week in June 1996.
August–September 1996 saw the discov-
ery of the CCR5 delta32 mutation, encod-
ing a truncated non-functional protein;
because of the high prevalence of this allele
in Caucasian populations coupled with
its simple Mendelian inheritance, CCR5
delta32 homozygosity provided the first
and only molecularly understood mecha-
nism for resistance to HIV infection. More-
over, this genotype was the basis for the
first, and still only, documented cure of
HIV infection. By October–November of
1996, both fusin and CCR5 were upgraded
from cofactors to true “coreceptors,” based
on demonstrations of their physical inter-
actions with Env. The findings that core-
ceptor engagement occurs only after CD4
binding means that designation of CD4
as the primary receptor refers not only
to its chronology of discovery but also to
its obligate mechanism of action. In the
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ensuing nearly two decades, the coreceptor
discoveries have engendered entirely new
paradigms for understanding HIV trans-
mission and pathogenesis, and have pro-
vided novel targets for antiretroviral drug
development and gene therapy strategies
aimed at curing HIV. In the chemokine
field, our fusin paper was quickly followed
(August 1996) by two back-to-back papers
identifying the CXC chemokine stromal
cell-derived factor 1 (SDF-1) as the nat-
ural ligand for fusin; SDF-1 was shown
to inhibit TCL-tropic but not M-tropic
HIV-1. Fusin was immediately renamed
CXCR4 in keeping with chemokine recep-
tor nomenclature. Thus, the impact of
finding fusin/CXCR4, the first “2nd recep-
tor” for HIV entry, endures to this day
and likely well into the future. The fusin
name, however, persists only in rare places
(Figure 1C).
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